Latest news with #HelmholtzMunich
Business Wire
2 days ago
- Business
- Business Wire
Taconic Biosciences Enters Into an Exclusive License Agreement With Helmholtz Munich to Expand Its CRISPR/Cas9 Gene Editing Services
RENSSELAER, N.Y.--(BUSINESS WIRE)-- Taconic Biosciences, a global leader in providing animal model solutions and services, entered into an exclusive license agreement with Helmholtz Munich, one of Germany's leading biomedical research centers, to provide preclinical researchers with advanced CRISPR gene editing services. By exclusively licensing Helmholtz Munich's groundbreaking gene editing techniques and applications, Taconic Biosciences strengthens its position as a leader in the commercialization of cutting-edge CRISPR gene editing services. Share Through this agreement, Taconic has acquired the exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich to improve the generation of genetically modified animal models for biomedical research. "Taconic is excited to expand our already extensive capabilities in CRISPR/Cas9 gene editing through this new partnership with Helmholtz Munich,' said Mike Garrett, Chief Executive Officer of Taconic Biosciences. 'This technology significantly enhances Taconic's ExpressMODEL ® platform to deliver high-quality, precise CRISPR/Cas9-generated custom animal models on an accelerated timeline to our customers." Taconic has been a pioneer in CRISPR/Cas9 gene editing services for over a decade and remains at the forefront of advanced gene-modification methodologies. By exclusively licensing Helmholtz Munich's groundbreaking gene editing techniques and applications, Taconic Biosciences strengthens its position as a leader in the commercialization of cutting-edge CRISPR gene editing services. "This agreement with Taconic will deepen our understanding of gene function by enabling the development of advanced, genetically engineered animal models," said Prof. Dr. Wolfgang Wurst, co-inventor of the licensed technology at Helmholtz Munich. "By combining our innovative CRISPR technology with Taconic's expertise in animal model generation and breeding, we aim to accelerate the creation of precise models that uncover the genetic basis of diseases — supporting scientific discovery and paving the way for future medical breakthroughs.' This partnership marks a significant milestone in Taconic's commitment to providing researchers with advanced tools for biomedical research. By integrating novel CRISPR/Cas9 technologies with proven expertise in model generation, the collaboration supports the rapid development of scientific breakthroughs and improved translation of genetic research into therapeutic innovation. To learn more about the ExpressMODEL ® CRISPR Platform and our Custom Model Generation Solutions, visit Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@ About Taconic Biosciences, Inc. Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions enabling customers to acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Yahoo
05-05-2025
- Health
- Yahoo
Osteoarthritis study could lead to new treatments
More than 900 genetic links to osteoarthritis, including 500 which have never been reported, have been uncovered in a research study in Sheffield. Sheffield Teaching Hospitals NHS Foundation Trust said the "landmark" global study into osteoarthritis was the largest of its kind. The degenerative condition affects around 595 million people globally, and is the leading cause of disability and chronic pain worldwide, according to the hospital trust. The genome study used genetic information from nearly two million people, and was published in the journal Nature. Led by Helmholtz Munich, the largest scientific research organisation in Germany, genetic codes and DNA of almost half a million osteoarthritis sufferers globally - including 1,000 volunteers from Sheffield - were compared with that of 1.5 million people without the disease, the trust said. The team identified 962 genetic variations more commonly found in those with osteoarthritis; more than 500 of which had not previously been identified, it said. The number osteoarthritis sufferers was predicted to rise to a billion people by 2050 and despite the impact "no disease-modifying treatments are currently available", researchers said. However the new work "paves the way for potential new drug treatments and personalised therapies," they continued. Prof Mark Wilkinson, Honorary Consultant Orthopaedic Surgeon at the trust and the University of Sheffield, said the findings were "hugely important" and would "open up exciting new avenues" for millions. "As well as identifying potential drug targets and opportunities for us to repurpose existing treatments that already target these genes in other conditions, this research has also significantly advanced our understanding of the underlying biological mechanisms associated with the disease," Prof Wilkinson said. Eight biological processes which regulate the body's internal systems and cell function were found, "shedding light on the disease's biological mechanisms", the trust said. Some of these genes contain proteins already targeted by drugs approved for other conditions, which could accelerate treatment development, it added. Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North. Sheffield Teaching Hospitals NHS Foundation Trust NHS: Osteoarthritis Nature Exercise to treat arthritis, new advice suggests
BBC News
05-05-2025
- Health
- BBC News
Global NHS osteoarthritis study could lead to new treatments
More than 900 genetic links to osteoarthritis, including 500 which have never been reported, have been uncovered in a research study in Teaching Hospitals NHS Foundation Trust said the "landmark" global study into osteoarthritis was the largest of its degenerative condition affects around 595 million people globally, and is the leading cause of disability and chronic pain worldwide, according to the hospital genome study used genetic information from nearly two million people, and was published in the journal Nature. Led by Helmholtz Munich, the largest scientific research organisation in Germany, genetic codes and DNA of almost half a million osteoarthritis sufferers globally - including 1,000 volunteers from Sheffield - were compared with that of 1.5 million people without the disease, the trust team identified 962 genetic variations more commonly found in those with osteoarthritis; more than 500 of which had not previously been identified, it number osteoarthritis sufferers was predicted to rise to a billion people by 2050 and despite the impact "no disease-modifying treatments are currently available", researchers the new work "paves the way for potential new drug treatments and personalised therapies," they continued. 'Repurpose existing treatments' Prof Mark Wilkinson, Honorary Consultant Orthopaedic Surgeon at the trust and the University of Sheffield, said the findings were "hugely important" and would "open up exciting new avenues" for millions."As well as identifying potential drug targets and opportunities for us to repurpose existing treatments that already target these genes in other conditions, this research has also significantly advanced our understanding of the underlying biological mechanisms associated with the disease," Prof Wilkinson biological processes which regulate the body's internal systems and cell function were found, "shedding light on the disease's biological mechanisms", the trust of these genes contain proteins already targeted by drugs approved for other conditions, which could accelerate treatment development, it added. Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
Gulf News
14-02-2025
- Health
- Gulf News
Intermittent fasting unsafe for teenagers, may impair cell development: Study
New Delhi: While intermittent fasting is hugely popular for weight loss and other health conditions, an animal study on Friday claimed it may be unsafe for teenagers, as it may impair their cell development. A team of German researchers from the Technical University of Munich (TUM), LMU Hospital Munich, and Helmholtz Munich showed that age plays a significant role in the outcomes of intermittent fasting. Intermittent fasting is a dietary approach, which restricts daily eating to one six- to eight-hour period each day, and is known to help people with diabetes, and heart disease besides enabling weight loss. The research, published in the journal Cell Reports, showed that chronic intermittent fasting disrupted the development of insulin-producing beta cells in young mice. "Our study confirms that intermittent fasting is beneficial for adults, but it might come with risks for children and teenagers," said Stephan Herzig, a professor at TUM and director of the Institute for Diabetes and Cancer at Helmholtz Munich. In the study adolescent, adult, and older mice remained without food for one day and were fed normally for two days. After 10 weeks, insulin sensitivity improved in both the adult and older mice, meaning that their metabolism responded better to insulin produced by the pancreas. This is key to regulating blood sugar levels and preventing conditions like Type 2 diabetes. However, the adolescent mice showed a troubling decline in their beta cell function - the insulin-producing cells of the pancreas. Insufficient insulin production is linked to diabetes and disrupted metabolism. "Intermittent fasting is usually thought to benefit beta cells, so we were surprised to find that young mice produced less insulin after the extended fasting," explained Leonardo Matta from Helmholtz Munich. When the team analysed the cause of the beta cell impairment in the pancreas, they found that the beta cells in the younger mice failed to mature properly. Comparing the findings with data from human tissues, the study showed that patients with Type 1 diabetes - where beta cells are destroyed by an autoimmune response - showed similar signs of impaired cell maturation. Sign up for the Daily Briefing Get the latest news and updates straight to your inbox
